NewAmsterdam Pharma Company NAMS Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $3.04M+2.1% | $32K-99.7% | $348K-98.8% | $19.15M+740% | $2.98M+113% | ||
| $38.01M-15.1% | $38.59M+10.6% | $30.97M-13.3% | $27.52M-28.3% | $44.75M+5.5% | ||
| $23.45M-13.6% | $27.42M+29.9% | $24.52M+33.2% | $27.26M+65.5% | $27.15M+87.9% | ||
| $61.46M-14.5% | $66.01M+17.9% | $55.49M+2.5% | $54.78M-0.1% | $71.9M+26.4% | ||
| $61.46M-14.5% | $66.01M+17.9% | $55.49M+2.5% | $54.78M-0.1% | $71.9M+26.4% | ||
| -$58.42M+15.2% | -$65.98M-52.6% | -$55.14M-121% | -$35.64M+32.2% | -$68.93M-24.2% | ||
| -1,921.7%+393pp | -206,187.5%-205,849pp | -15,845.7%-15,760pp | -186.1%+2,121pp | -2,314.5%+1,646pp | ||
| $5.65M-23.1% | $6.47M+44.3% | $6.71M+51.1% | $7.06M+44.9% | $7.35M+138% | ||
| -$1.61M-138% | $0+100% | $218K-95.3% | $8.63M+968% | $4.29M+278% | ||
| -$48.44M-22.6% | -$74.92M+18.7% | -$72.01M-333% | -$17.36M+55.5% | -$39.53M+57.8% | ||
| —— | —— | —— | —— | —— | ||
| -$48.44M-22.6% | -$74.92M+18.7% | -$72.01M-333% | -$17.36M+55.5% | -$39.53M+57.8% | ||
| -1,593.5%-266pp | -234,134.4%-233,413pp | -20,691.1%-20,634pp | -90.7%+1,621pp | -1,327.3%+5,366pp | ||
| -$0.40-17.6% | -$0.63+33.7% | -$0.61-239% | -$0.15+63.4% | -$0.34+67.9% | ||
| -$0.40-17.6% | -$0.63+33.7% | -$0.61-239% | -$0.15+63.4% | -$0.34+67.9% | ||
| —— | —— | —— | —— | -$3.99M-146% | ||
| -$5.94M+56.8% | $15.34M-21.7% | $23.79M+612% | -$2.59M+60.7% | -$13.76M-145% | ||
| -$49.01M-23.9% | -$74.77M+18.8% | -$71.69M-331% | -$17.47M+55.2% | -$39.56M+57.8% | ||
| -$1.61M-138% | $0+100% | $218K-95.3% | $8.63M+968% | $4.29M+278% | ||
| -$12K— | -$11K— | -$1K— | —— | —— | ||
| -$572K-1,633% | $153K+1,260% | $313K+2,682% | -$107K-1,051% | -$33K-393% | ||
| $3.04M+2.1% | $32K-99.7% | $348K-98.8% | $19.15M+740% | $2.98M+113% | ||
| -$58.42M+15.2% | -$65.98M-52.6% | -$55.14M-121% | -$35.64M+32.2% | -$68.93M-24.2% | ||
| -$58.36M+15.3% | -$65.92M-52.7% | -$55.08M-121% | -$35.59M+32.3% | -$68.87M-24.2% | ||
| -$58.36M+15.3% | -$65.92M-52.7% | -$55.08M-121% | -$35.59M+32.3% | -$68.87M-24.2% | ||
| -1,919.7%+393pp | -206,003.1%-205,665pp | -15,827.3%-15,742pp | -185.9%+2,120pp | -2,312.7%+1,646pp | ||
| -$58.42M+15.2% | -$65.98M-52.6% | -$55.14M-121% | -$35.64M+32.2% | -$68.93M-24.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does NewAmsterdam Pharma Company's income statement data come from?
- Every line is extracted from NewAmsterdam Pharma Company's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.